M William Audeh, MD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Languages
- English,
Gender
Male
Experience
41 Years
Locations
Samuel Oschin Cancer Center
Samuel Oschin Cancer Center
- Pavilion is located at 127 S. San Vicente Boulevard between West 3rd Street and Gracie Allen Drive. Valet parking and self-parking are available in the Pavilion Parking lot, located on Sherbourne Drive between West 3rd Street and Gracie Allen Drive. Park in the Gold Zone (Levels B2 and B3) and take the Gold Parking elevators to the Plaza Level. Follow the signs for the Pavilion elevators, and take the elevator up to your destination. For parking rates and hours of operation, please visit cedars-sinai.org/parking
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- IM Hematology Oncology
Programs
Research Areas
Education & Training
-
Stanford Medical Center
Fellowship - Completed 1989
-
Stanford Medical Center
Residency - Completed 1986
-
University of Iowa
Medical School - Completed 1982
-
University of Minnesota
Degrees - Completed 1978
-
Carleton College
Degrees - Completed 1977
Achievements
-
2
Board Certifications
-
5
Awards and Honors
Board Certifications
-
General Internal Medicine
American Board of Internal Medicine
-
IM/Oncology
American Board of Internal Medicine
Awards and Honors
- Member, American Association of Cancer Research
- American Cancer Society Clinical Fellowship in Oncology
- Member, American Society of Human Genetics
- Member, American Society of Clinical Oncology
- William R. Wilson Award for Excellence in Internal Medicine
Publications
- Audeh, MW. Genetic Predisposition to Cancer – Malfunction or Maladaptation?. Horizons in Cancer Therapeutics –From Bench to Bedside. 2003;4:3-18.
- Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
- Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
- Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med. 2014;7:307-316.